Identification of Small Molecule Compounds That Selectively Inhibit Varicella-Zoster Virus Replication
Open Access
- 15 February 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (4) , 2349-2358
- https://doi.org/10.1128/jvi.77.4.2349-2358.2003
Abstract
A series of nonnucleoside, N -α-methylbenzyl- N ′-arylthiourea analogs were identified which demonstrated selective activity against varicella-zoster virus (VZV) but were inactive against other human herpesviruses, including herpes simplex virus. Representative compounds had potent activity against VZV early-passage clinical isolates and an acyclovir-resistant isolate. Resistant viruses generated against one inhibitor were also resistant to other compounds in the series, suggesting that this group of related small molecules was acting on the same virus-specific target. Sequencing of the VZV ORF54 gene from two independently derived resistant viruses revealed mutations in ORF54 compared to the parental VZV strain Ellen sequence. Recombinant VZV in which the wild-type ORF54 sequence was replaced with the ORF54 gene from either of the resistant viruses became resistant to the series of inhibitor compounds. Treatment of VZV-infected cells with the inhibitor impaired morphogenesis of capsids. Inhibitor-treated cells lacked DNA-containing dense-core capsids in the nucleus, and only incomplete virions were present on the cell surface. These data suggest that the VZV-specific thiourea inhibitor series block virus replication by interfering with the function of the ORF54 protein and/or other proteins that interact with the ORF54 protein.Keywords
This publication has 31 references indexed in Scilit:
- The UL6 Gene Product Forms the Portal for Entry of DNA into the Herpes Simplex Virus CapsidJournal of Virology, 2001
- A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene ProductsJournal of Virology, 2001
- Herpes Simplex Virus DNA Cleavage and Packaging Proteins Associate with the Procapsid prior to Its MaturationJournal of Virology, 2001
- Novel agents for the therapy of varicella-zoster virus infectionsExpert Opinion on Investigational Drugs, 2000
- Nucleotide Sequences that Distinguish Oka Vaccine from Parental Oka and Other Varicella?Zoster Virus IsolatesThe Journal of Infectious Diseases, 2000
- Current Pharmacological Approaches to the Therapy of Varicella Zoster Virus InfectionsDrugs, 1999
- Varicella-Zoster Virus ORF61 Deletion Mutants Replicate in Cell Culture, but a Mutant with Stop Codons in ORF61 Reverts to Wild-Type VirusVirology, 1998
- Postherpetic Neuralgia — Pathogenesis, Treatment, and PreventionNew England Journal of Medicine, 1996
- Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCVAntiviral Research, 1995
- The Complete DNA Sequence of Varicella-Zoster VirusJournal of General Virology, 1986